摘要心血管病是引起麻醉及术后死亡的首要原因.为了降低围术期并发症的风险性,识别潜在冠脉疾病以启动适当治疗策略很重要.最新发现按简单、安全、精确以及经济有效原则将围手术期风险进行分级.利尿肽有望成为围手术期新的风险标记物.β受体阻断剂的抗缺血特性已被证实,在临床实践中,使用足够剂量的β受体阻断剂,加强围手术期心率控制及术后持续的β受体阻断剂使用或许成为抗缺血的重要因素.他汀类虽然有望成为围手术期具心肌保护特性的药物,但还需要更多临床试验验证.现就探讨围术期治疗领域的新理念,以运用于临床实践或促进更深远研究作一综述.

abstractsCardiovascular events are the leading cause of post-anesthetic and.surgical death.Preoperative identiffcation of undedying coronary artery disease and initiation of appropriate treatment strategies are important to reduce the occurrence of perioperative complication.Recent findings have developed preoperative risk classification in terms of simplicity,safety,accu-ra-cy and cost-effectiveness.Natriuretic peptides are expected to become new preoperative risk markers.The anti-ischemic prop-erties of β-blockers have been demonstrated in clinical practice.Although statins have emerged as promising drugs with peri operative cardio-protective properties,more clinical evidences ale needed.The present review discusses the new insights in the field of perioperative management in order to promote its clinical application and further study.